FDA moves ahead with safety study of abortion pill mifepristone The FDA is proceeding with a safety study of the abortion pill mifepristone, a development that may pave the way for restrictions on the medication. This retrospective study, involving hundreds of thousands of cases, could have interim results as early as July. The review has become a focal point of political debate, with critics arguing the agency is attempting to restrict access, while supporters maintain mifepristone is safe and effective.

• The FDA is conducting a safety study of the abortion pill mifepristone.
• This study could lead to restrictions on the medication’s access.
• The study is retrospective and involves hundreds of thousands of cases.
• Interim results may be released in July, with final results depending on further analysis.
• The Biden administration lifted restrictions on mifepristone, allowing telehealth and mail delivery, which has faced legal challenges.
• Planned Parenthood CEO Alexis McGill Johnson called the review a “politically motivated farce” and expressed concern about the Trump administration attempting to limit abortion access.
• While a ban is unlikely, the study’s findings could limit access through telehealth or mail, or restrict prescribing authority.